Aug 13 |
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
Jul 19 |
Cidara Therapeutics files for 16.8M common stock offering
|
Jul 3 |
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
May 30 |
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
|
May 15 |
Cidara Therapeutics GAAP EPS of -$2.28 beats by $0.11, revenue of $8.46M misses by $0.57M
|
May 15 |
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
May 15 |
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
|
Apr 26 |
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
|
Apr 26 |
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
|
Apr 25 |
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|